A Pivotal Spring Agenda for CorMedix Investors
CorMedix is entering a crucial period this spring, marked by investor conferences, the release of Q4 earnings, and significant clinical readouts. The company will participate in several healthcare conferences in March and has authorized a new $75 million share repurchase program. Key clinical trial results for REZZAYO (Phase III "ReSPECT" trial) and development efforts for DefenCath are also anticipated in 2026, which could significantly impact the company's commercial potential.
A Pivotal Spring Agenda for CorMedix Investors
CorMedix is entering a critical period with several key events scheduled for the spring of 2026, including investor conferences in March, the release of Q4 earnings, and a new $75 million share repurchase program. Additionally, significant clinical data readouts are anticipated in Q2 2026 for its drug REZZAYO from the Phase III "ReSPECT" trial, and further development for DefenCath. These activities are expected to significantly influence the company's near-term trajectory and investor perception.
Understanding the Setup: (CRMD) and Scalable Risk
This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting weak near and mid-term sentiment, and a neutral long-term outlook. It identifies elevated downside risk due to a lack of additional long-term support signals. The report also provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles.
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
CorMedix (CRMD) shares have dropped 27% over the past three months due to a cautious 2026 financial outlook, primarily for its lead product DefenCath. Despite initial strong uptake for DefenCath and the acquisition of Melinta Therapeutics for diversification, concerns about slower adoption and increased competition from larger pharmaceutical companies have impacted investor sentiment. The article suggests that due to recent price declines, conservative guidance, and downward earnings revisions, investors might consider reducing their positions or exiting the stock.
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback
CorMedix Inc. (CRMD) announced that its Board of Directors has authorized a multi-year stock repurchase program of up to $75 million. This program will allow the company to buy back shares of its common stock through various methods, depending on market conditions. The repurchases are expected to be funded by cash generated from CorMedix's operations.
CorMedix Inc. (CRMD) Investor Outlook: 101.86% Potential Upside Sparks Interest
CorMedix Inc. (NASDAQ: CRMD) is highlighted as an intriguing prospect for biotechnology investors, with analysts projecting a 101.86% potential upside. The company, focused on solutions for life-threatening diseases and holding a market cap of $579.89 million, has seen impressive revenue growth and strong operational efficiency. Despite current trading prices below moving averages, an RSI close to oversold territory, and strong analyst ratings, suggest a potential buying opportunity with an average target price of $14.86.
CorMedix Buyback And Melinta Deal Recast Infection Control Growth Story
CorMedix has authorized a $75 million share repurchase program and is acquiring Melinta Therapeutics, signaling a strategic shift towards a broader multi-product specialty pharmaceutical portfolio. These developments, along with ongoing progress on Rezzayo and DefenCath, aim to diversify revenue and reduce dependence on single products. Investors are focused on integration execution, product advancement, and potential challenges like clinical hurdles and cost synergies.
CorMedix to Participate in Upcoming Investor Conferences
CorMedix, Inc. (Nasdaq: CRMD), a biopharmaceutical company, announced its senior management will present and participate in investor meetings at three upcoming conferences in March: the Leerink Partners Global Healthcare Conference, the Citizens Life Sciences Conference, and the Barclays 28th Annual Global Healthcare Conference. The presentations will include fireside chats at the first two events, while the Barclays conference will feature one-on-one investor meetings. CorMedix will discuss its focus on therapeutic products for life-threatening diseases, including its commercialized DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics LLC.
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Therapeutics (Nasdaq: CRMD) announced its senior management will participate in investor conferences in March 2026. The company will be presenting at the Leerink Partners Global Healthcare Conference and the Citizens Life Sciences Conference, and holding one-on-one meetings at the Barclays 28th Annual Global Healthcare Conference. CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics.
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Therapeutics announced that its senior management will present and participate in investor meetings at three upcoming investor conferences in March: the Leerink Partners Global Healthcare Conference, the Citizens Life Sciences Conference, and the Barclays 28th Annual Global Healthcare Conference. The company, a biopharmaceutical firm focused on life-threatening conditions, will provide updates on its commercial products like DefenCath® and its anti-infective portfolio acquired from Melinta Therapeutics. They will also discuss ongoing clinical studies and anticipated topline results for REZZAYO® in Q2 2026.
Cormedix (CRMD) Receives Unchanged 'Buy' Rating from D. Boral Ca
D. Boral Capital has reiterated its 'Buy' rating for Cormedix (CRMD), maintaining a price target of $14.00. This comes amidst mixed price target adjustments from other analysts, although the consensus among 7 brokerage firms indicates an "Outperform" status for CRMD. Cormedix is a biopharmaceutical company focused on developing therapies for life-threatening diseases, with a primary focus on the commercialization of DefenCath in the US.
CorMedix Buyback And Melinta Deal Recast Infection Control Growth Story
CorMedix has announced a significant share repurchase program and plans to acquire Melinta Therapeutics, aiming to transform into a broader specialty pharmaceutical company. Despite recent stock declines, the company has shown long-term strength, and these strategic moves, alongside progress on Rezzayo and DefenCath, are crucial for future growth. Investors will be monitoring the integration of Melinta and the advancement of CorMedix's product pipeline to assess the company's execution and potential for diversified revenue.
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback
CorMedix Inc. (CRMD) has announced that its board of directors approved a multi-year stock repurchase program, authorizing the company to buy back up to $75 million of its common stock. This program signals management's confidence in the company's future and aims to enhance shareholder value.
CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback
CorMedix Inc. (CRMD) announced that its board of directors approved a multi-year share repurchase program, authorizing up to $75 million in common stock buybacks through December 31, 2027. The company's decision is based on its strong balance sheet, operating performance, and projected future cash flow, allowing flexibility for internal growth and strategic investments. CorMedix expects to begin repurchases in Q1 2026, supported by approximately $150 million in cash and equivalents and 79.3 million shares outstanding as of December 31, 2025.
Citizens reiterates Market Outperform rating on CorMedix stock By Investing.com
Citizens has reiterated its Market Outperform rating and $18.00 price target on CorMedix (NASDAQ:CRMD) following the company's Analyst Day, citing the significant upside potential from REZZAYO, particularly in fungal infection prophylaxis which represents a market exceeding $2 billion. Despite the positive outlook, other analyst firms like H.C. Wainwright, Leerink Partners, and Truist Securities have recently lowered their price targets due to updated guidance and revenue outlooks. CorMedix also announced a $75 million share repurchase program set to begin in Q1 2026.
10 Best Long Term Healthcare Stocks to Buy
This article identifies CorMedix Inc. (NASDAQ: CRMD) as one of the best long-term healthcare stocks to buy. CorMedix announced a $75 million share repurchase program, reflecting confidence in its financial health and future cash flow. The company, a commercial-stage biopharmaceutical firm focusing on infection prevention, also saw insider selling activity by an executive, which the article notes is typically monitored closely by investors in smaller-cap biotech firms.
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
CorMedix Inc.'s shares have fallen by 35% in the last month, leading to a 30% drop over the past year. The company's price-to-sales (P/S) ratio of 2.7x is lower than the industry average, which could signal undervaluation. However, analysts predict future revenue growth for CorMedix will be lower than the broader pharmaceutical industry, potentially explaining its low P/S ratio and current share price performance.
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
CorMedix Inc. (NASDAQ:CRMD) shares have dropped significantly by 35% over the last month, leading to a 30% decline over the past year. Despite its current low price-to-sales (P/S) ratio of 2.7x, which is below the industry average, analysts forecast slower revenue growth for CorMedix compared to the broader pharmaceuticals industry. This outlook on more muted future growth explains the company's lower P/S ratio and suggests that shareholders are not anticipating a strong share price recovery soon.
CorMedix stock rises after announcing $75 million share buyback plan
CorMedix Inc. (NASDAQ:CRMD) stock increased by 5.7% after the biopharmaceutical company announced a $75 million share repurchase program. The company's board authorized the buyback of outstanding common stock until December 31, 2027, with repurchases expected to start in the first quarter of 2026. CorMedix aims to return value to shareholders while maintaining financial flexibility for growth and potential inorganic opportunities.
CorMedix stock rises after announcing $75 million share buyback plan By Investing.com
CorMedix Inc. (NASDAQ:CRMD) stock increased by 5.7% after the biopharmaceutical company announced a $75 million share repurchase program. The buyback, authorized by the board, allows for repurchases of common stock through December 31, 2027, with the company aiming to start in Q1 2026. This initiative is supported by a strong balance sheet and is intended to return value to shareholders while maintaining financial flexibility for growth.
CorMedix Therapeutics Announces Share Repurchase Program
CorMedix Therapeutics (Nasdaq: CRMD) has announced a share repurchase program, authorized by its Board of Directors, to buy back up to $75 million of its outstanding common stock through December 31, 2027. This decision is supported by the company's strong balance sheet, solid operating performance, and expected cash flow generation. The program aims to return value to shareholders while maintaining financial flexibility for growth and potential inorganic opportunities.
Biotech CorMedix sets $75M stock buyback, eyes Q1 2026 start
CorMedix Therapeutics has announced a Board-authorized share repurchase program of up to $75 million of common stock through December 31, 2027. The company, which had approximately $150 million in cash and 79.3 million shares outstanding as of Dec 31, 2025, expects repurchases to begin as early as Q1 2026. This move is intended to return value to shareholders while maintaining financial flexibility for growth, including potential inorganic opportunities.
CorMedix Therapeutics Announces Share Repurchase Program
CorMedix Therapeutics (Nasdaq: CRMD) has announced that its Board of Directors approved a share repurchase program, authorizing the company to repurchase up to $75 million of its outstanding common stock through December 31, 2027. The biopharmaceutical company highlighted its strong balance sheet and expected cash flow generation as factors enabling this program. The company aims to return value to shareholders while maintaining financial flexibility for growth and potential inorganic opportunities.
H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance
H.C. Wainwright and RBC Capital recently lowered price targets for CorMedix Inc. (CRMD) to $13, while maintaining Buy and Outperform ratings, respectively. The adjustments reflect updated guidance related to DefenCath and a shift in focus towards clinical results rather than commercial performance for the company's future. CorMedix Inc. is a biopharmaceutical company with an FDA-approved catheter lock solution, DefenCath, designed to reduce bloodstream infections in hemodialysis patients.
H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance
H.C. Wainwright has lowered its price target for CorMedix Inc. (CRMD) to $13 from $18 but maintained a Buy rating, reflecting updated guidance for DefenCath. The firm indicated that CRMD's future success will now be more dependent on clinical results than commercial performance. RBC Capital also reduced its price target to $13 from $22, while keeping an Outperform rating, after updating models for biotech companies.
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedix (CRMD) has seen its stock drop 31% in the past month due to a conservative 2026 financial outlook for its lead product, DefenCath, leading to investor concerns about its growth trajectory. Despite DefenCath's unique market position and the recent Melinta acquisition aimed at diversification, increased competition and downward revisions to earnings estimates suggest a challenging near-term future for the stock. Zacks Investment Research currently rates CRMD as a "Strong Sell."
CorMedix Inc. (CRMD) Stock Analysis: Exploring an 85% Potential Upside with Strong Buy Ratings
CorMedix Inc. (NASDAQ: CRMD) is an intriguing biotechnology company specializing in catheter-related bloodstream infections, with its lead product DefenCath. The stock shows a potential upside of 85.25% based on analyst target prices, driven by an impressive 810.20% revenue growth and a high return on equity. While valuation metrics are mixed, the company has unanimous buy ratings from analysts, and its reinvestment of profits for growth appeals to long-term investors.
Why CorMedix is spotlighting two Phase III drugs at its Feb. 10 analyst day
CorMedix Therapeutics announced it will host an in-person and virtual Analyst Day in New York on February 10, 2026, from 1:00 PM to 3:00 PM Eastern. The company plans to provide portfolio and pipeline updates, discuss growth drivers, and highlight upcoming milestones. The event will feature key opinion leaders and senior management, focusing on its Phase III programs, REZZAYO for fungal infections prophylaxis and DefenCath for reducing CLABSI in TPN patients.
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
CorMedix Therapeutics (Nasdaq: CRMD) will host an in-person and virtual analyst day on February 10, 2026, in New York to discuss its portfolio, pipeline, growth drivers, and upcoming milestones. The event will feature key opinion leaders and senior management, focusing on market dynamics, unmet medical needs, and the commercial opportunities for its REZZAYO® and DefenCath® programs. Attendance for the in-person event is limited to analysts and institutional investors.
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
CorMedix Therapeutics will host an in-person and virtual analyst day in New York on February 10, 2026, from 1:00 PM to 3:00 PM Eastern. The event will provide updates on the company's portfolio and pipeline, highlighting key growth drivers and upcoming milestones. Presentations will include insights into unmet medical needs and the commercial opportunities for REZZAYO® and DefenCath® programs.
CorMedix director Dillione sells $68,800 in shares
CorMedix Inc. director Janet Dillione sold 10,000 shares of common stock for a total of $68,800. This transaction follows recent company news including preliminary Q4 and full-year 2025 revenue figures, 2026 revenue guidance, and leadership changes, which led to analysts lowering price targets for the company.
CorMedix director Dillione sells $68,800 in shares By Investing.com
CorMedix director Janet Dillione sold 10,000 shares of common stock for $68,800, bringing her direct ownership to 38,473 shares. Simultaneously, CorMedix reported preliminary unaudited Q4 2025 net revenue of $127 million and full-year 2025 revenue of $310 million, along with leadership changes. Analysts have since lowered price targets for CorMedix due to lower-than-expected 2026 revenue guidance.
CorMedix (CRMD) price target decreased by 11.28% to 17.19
The article reports that the price target for CorMedix (CRMD) has been decreased by 11.28%, bringing it down to $17.19. This change reflects a revised outlook on the company's stock by analysts.
Witnessing An Insider Decision, Joseph Todisco Exercises Options Valued At $93K At Cormedix
Joseph Todisco, CEO of Cormedix (NASDAQ: CRMD), recently exercised stock options for 29,585 shares valued at $93,784, according to a recent SEC filing. The biopharmaceutical company, focused on developing therapies for life-threatening diseases, shows positive financial trends with strong revenue growth and high gross margins, despite challenges in debt management. Insider transactions like this can signal executive confidence in the company's future.
CorMedix Inc (NASDAQ:CRMD) Exemplifies a High-Growth Stock Screen Methodology
CorMedix Inc (NASDAQ:CRMD) aligns with "The Little Book That Makes You Rich" methodology due to its strong financial performance, including significant year-over-year revenue and earnings growth, positive earnings surprises, and high return on equity. The article highlights CorMedix's potential as a high-growth stock, driven by the anticipated market introduction of its key product, DefenCath, despite moderate financial condition scores. This analysis positions CRMD as an interesting case for both growth and value investors looking for efficient capital use and robust company growth.
CorMedix (CRMD) Is Down 11.1% After CEO Becomes Chair And Sets 2026 Revenue Target - Has The Bull Case Changed?
CorMedix recently restructured its leadership, with CEO Joseph Todisco now also serving as Chairman, and appointed Mike Seckler as EVP & Chief Commercial Officer, alongside providing new 2026 revenue guidance of US$300 million to US$320 million. This move aims to provide a clearer vision for investors on the company's growth strategy, particularly focusing on the successful integration of the Melinta acquisition and commercialization of its anti-infective portfolio. The market's reaction to these changes, including a stock price drop, highlights investor focus on execution risks despite the positive revenue outlook and potential for a significant upside as projected by some analysts.
CorMedix (CRMD) Is Down 11.1% After CEO Becomes Chair And Sets 2026 Revenue Target - Has The Bull Case Changed?
CorMedix (CRMD) recently restructured its leadership, with CEO Joseph Todisco becoming Chairman and Mike Seckler joining as EVP & Chief Commercial Officer. The company also issued new 2026 revenue guidance of US$300 million to US$320 million, which aims to provide clearer insight into its growth strategy. While the new leadership and revenue targets sharpen expectations, the core investment thesis still relies heavily on the successful integration of Melinta and the commercial scaling of its anti-infective portfolio.
CorMedix (CRMD) Is Down 11.1% After CEO Becomes Chair And Sets 2026 Revenue Target - Has The Bull Case Changed?
CorMedix recently appointed CEO Joseph Todisco as Chairman of the Board, added Mike Seckler as EVP & Chief Commercial Officer, and provided new 2026 revenue guidance of US$300-320 million. These changes aim to offer clearer insight into the company's growth strategy, particularly focusing on the successful integration of the Melinta acquisition and commercialization of its anti-infective portfolio. Despite a projected $19.00 fair value based on future revenue and earnings, the article highlights the reliance on successful integration and continued uptake of a few key anti-infective assets as central issues for CorMedix's actual performance.
CorMedix (CRMD) price target decreased by 11.28% to 17.19
The article reports that the price target for CorMedix (CRMD) has been decreased by 11.28%, bringing it down to $17.19. This information indicates a revised outlook for the company's stock by analysts.
Breaking Update: Steven Lefkowitz Engages In Options Exercise At Cormedix Realizing $22K
Cormedix Board Member Steven Lefkowitz exercised stock options for 15,000 shares of CRMD, valued at $22,275, as disclosed in an SEC filing on January 15, 2026. The biopharmaceutical company demonstrated impressive Q3 2025 revenue growth of 810.22% and strong profitability metrics, though its debt-to-equity ratio is higher than industry norms. The article also provides a detailed financial breakdown of Cormedix, including its valuation metrics and the significance of insider transactions.
Is It Time To Reassess CorMedix (CRMD) After The Sharp Recent Share Price Slide
CorMedix (CRMD) has experienced a significant share price decline, making it appear potentially mispriced. Simply Wall St's analysis, using a Discounted Cash Flow (DCF) model and Price/Earnings (P/E) ratio, suggests the stock is currently undervalued. The article encourages investors to delve deeper into the company's valuation using various analytical approaches.
Is It Time To Reassess CorMedix (CRMD) After The Sharp Recent Share Price Slide
CorMedix (CRMD) shares have experienced a significant decline recently, prompting an analysis of its underlying value. According to Simply Wall St's discounted cash flow analysis, CorMedix appears heavily undervalued, with an estimated intrinsic value of $72.83 per share compared to its recent price of $7.09. The company also trades at a P/E ratio significantly below its industry average and Simply Wall St's calculated "Fair Ratio," further suggesting it may be mispriced.
CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance
CorMedix (CRMD) has appointed Joseph Todisco as Chairman and issued 2026 revenue guidance of US$300-US$320 million, following a significant share price decline. Despite recent underperformance, the company is seen as undervalued with a fair value of US$19.00, driven by the acquisition of Melinta Therapeutics and projected operational efficiencies. The article suggests investors consider potential integration costs and regulatory risks.
CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance
CorMedix (CRMD) is attracting attention after appointing Joseph Todisco as Chairman and Mike Seckler as EVP & Chief Commercial Officer, along with issuing 2026 revenue guidance of US$300 million to US$320 million. Despite a recent share price decline, the company is considered undervalued by many models, trading at US$7.15 against a fair value of US$19.00. This valuation is supported by the acquisition of Melinta Therapeutics, which is expected to diversify revenue and generate significant operating expense synergies, though integration costs and regulatory risks remain potential concerns.
CRMD: 2026 will be a transitional year, with growth driven by new indications and pipeline catalysts
CorMedix Inc. (CRMD) anticipates 2026 to be a transitional year, building on record 2025 revenues powered by DefenCath and Melinta, despite a transitional reimbursement period. Future growth is projected through new indications for DefenCath, the phase 3 readout for Rezzayo, and strategic business development, all supported by a strong financial position and intellectual property. This outlook is based on insights from the 44th Annual J.P. Morgan Healthcare Conference.
CorMedix Therapeutics Announces Leadership and Board Updates
CorMedix Therapeutics has announced key leadership and board changes. CEO Joseph Todisco has extended his contract and will also become Chairman of the Board, while Myron Kaplan transitions to Lead Independent Director. Additionally, Mike Seckler has been appointed as EVP & Chief Commercial Officer to bolster the company's diversified commercial operations and pipeline.
CorMedix (NASDAQ: CRMD) boosts CEO pay and names him board chair
CorMedix Inc. has increased CEO Joseph Todisco's annual base salary from $665,000 to $750,000 and his target annual bonus from 65% to 75% of base salary, effective January 1, 2026. Additionally, Todisco will assume the role of Chairman of the board of directors starting January 8, 2026, consolidating leadership and board oversight. The company also reported preliminary financial results for the quarter and year ended December 31, 2025, which are subject to audit and accounting adjustments.
CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Revenue Outlook And Reshuffling Leadership
CorMedix (CRMD) experienced a 35.4% stock drop after revising its 2026 revenue guidance to US$300-320 million and announcing leadership changes. CEO Joseph Todisco now also serves as Chairman, with Mike Seckler joining as EVP & CCO, signaling a focus on commercial execution and post-Melinta acquisition integration. The reduced revenue outlook is primarily linked to upcoming changes in DefenCath reimbursement methodology.
Why CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Guidance And Revamping Its Leadership Structure
CorMedix Inc. (CRMD) saw its stock drop by 35.4% following its updated 2026 revenue guidance of US$300 million to US$320 million and a strategic leadership restructuring. The revised revenue outlook, primarily influenced by changes in DefenCath reimbursement, along with CEO Joseph Todisco becoming Chairman and Mike Seckler joining as EVP & Chief Commercial Officer, indicates a recalibration of the company's financial and governance strategies. This news underscores reimbursement as a primary operational risk for CorMedix, impacting immediate revenue expectations but not fundamentally altering the long-term product thesis.
Drugmaker CorMedix makes its CEO board chair and hires new commercial chief
CorMedix Therapeutics announced leadership changes, with CEO Joseph Todisco also becoming Chairman of the Board, and Myron Kaplan transitioning to Lead Independent Director. The company also appointed Mike Seckler as EVP & Chief Commercial Officer, highlighting its evolution into a diversified commercial operation with positive cash flow. Despite these positive strategic moves, CorMedix's stock (CRMD) declined 32.77% on the news, reflecting a negative market reaction possibly due to governance concerns or profit-taking.
